Full Press Release Details
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors.
IDYA
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors
Key Takeaway: IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof of Concept for Potential First in Class PARG Inhibitor IDE161 in HRD Solid Tumors